C4 Therapeutics Inc

For the period ended Sep 30, 2024. Filed Oct 31, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Oct 31, 2024

CCCC$3.00-4.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statement of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue from collaboration agreements	$15,362	$11,072	$30,407	$17,495
Operating expenses:
Research and development	31,838	28,347	78,124	87,315
General and administrative	11,768	10,533	31,751	31,784
Restructuring	—	—	2,437	—
Total operating expenses	43,606	38,880	112,312	119,099
Loss from operations	(28,244)	(27,808)	(81,905)	(101,604)
Other income (expense), net:
Interest expense and amortization of long-term debt − related party	—	(167)	—	(1,373)
Loss on early extinguishment of debt	—	(621)	—	(621)
Interest and other income, net	3,578	2,562	11,162	6,862
Total other income, net	3,578	1,774	11,162	4,868
Loss before income taxes	(24,666)	(26,034)	(70,743)	(96,736)
Income tax expense	—	(1,003)	—	(1,003)
Net loss	$(24,666)	$(27,037)	$(70,743)	$(97,739)
Net loss per share − basic and diluted	$(0.35)	$(0.55)	(1.03)	(1.99)
Weighted-average shares outstanding − basic and diluted	69,627,190	49,212,126	68,958,938	49,103,351
Other comprehensive loss:
Unrealized gain on marketable securities	895	870	582	3,233
Comprehensive loss	$(23,771)	$(26,167)	$(70,161)	$(94,506)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.